Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions. With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.
How does Organon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Organon's score of 34 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Organon reported total carbon emissions of approximately 7,200,000 kg CO2e from Scope 1 and Scope 2 sources, with Scope 1 emissions at about 2,272,000 kg CO2e and Scope 2 emissions at approximately 5,557,000 kg CO2e (market-based). Additionally, Scope 3 emissions were significant, with business travel contributing about 415,000 kg CO2e, employee commute at approximately 830,000 kg CO2e, and waste generated in operations at around 130,000 kg CO2e. For 2022, Organon’s emissions were slightly lower, with Scope 1 emissions at about 1,122,000 kg CO2e and Scope 2 emissions (market-based) at approximately 5,677,000 kg CO2e. The company also reported substantial Scope 3 emissions, totalling around 1,029,000,000 kg CO2e globally, primarily driven by purchased goods and services. Organon has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 GHG emissions by more than 25% from 2020 levels by 2025. This target reflects a proactive approach to mitigating climate impact and aligns with industry standards for sustainability. The emissions data is not cascaded from any parent organisation, and all figures are reported directly by Organon. The company continues to focus on enhancing its sustainability practices and reducing its carbon footprint in the pharmaceutical sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 00,000,000 | 
| Scope 2 | 32,908,000 | 00,000,000 | 00,000,000 | 
| Scope 3 | - | - | 0,000,000,000 | 
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 74% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Organon has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
